Natco Pharma Ltd. (NATCOPHARM) 52 Week Low Streak: Why the decline persists
- October 14, 2026
- Posted by: Kunal Singla
- Category: News
Natco Pharma Ltd. (NATCOPHARM) has now set a fresh 52-week low for its second straight session, and the Natco Pharma Ltd. 52 Week Low Streak is down 1.27% across the run. The latest trough stood at Rs 786.2, while the latest traded price was Rs 790 at 14 October 2026 at 9:22 AM IST. Univest data confirms the pattern, but it does not establish a company-specific cause for the repeated decline.
With a market capitalisation of Rs 15,697.36 crore, the Natco Pharma Ltd. 52 Week Low Streak matters because it shows a repeated one-year breakdown rather than a single-day slip. For readers tracking Natco Pharma Ltd. 52 Week Low Streak, the focus is not only the latest tick lower, but also how the fresh low compares with the earlier trough and how the valuation now looks after two sessions of weakness.
What the Repeated 52-Week Lows Show
Natco Pharma Ltd. 52 Week Low Streak now confirms a repeated one-year low pattern over two consecutive sessions, with the full streak down 1.27%. The first low in the run was set on 13 October 2026, and the latest session pushed the stock to Rs 786.2 again. Natco Pharma Ltd. 52 Week Low Streak is therefore best understood as an extended decline pattern, not as a one-off close to the low.
For Natco Pharma Ltd. 52 Week Low Streak, the practical takeaway is simple: the stock has not yet reclaimed the level that would break the sequence of yearly lows. Because no company-specific catalyst is confirmed, the streak itself becomes the main fact to track. Natco Pharma Ltd. 52 Week Low Streak also matters because repeated lows often draw attention to whether the market is still willing to reprice the business lower session after session.
Natco Pharma Ltd. (NATCOPHARM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 15,697.36 crore |
| P/E Ratio | 13.54x |
| P/B Ratio | 1.66x |
| ROE | 16.3% |
| ROCE | 17.16% |
| EPS | Rs 58.33 |
| Book Value Per Share | Rs 476.47 |
| Dividend Yield | 0.63% |
Natco Pharma Ltd. (NATCOPHARM) fundamental metrics show P/E 13.54x, P/B 1.66x, ROE 16.3%, ROCE 17.16%. Taken on their own, these numbers offer context rather than a trading signal.
Natco Pharma Ltd. has a market capitalisation of Rs 15,697.36 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 13.54x, P/B at 1.66x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 16.3% and ROCE of 17.16%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 58.33, book value per share of Rs 476.47, dividend yield of 0.63%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.8x, median ROE of 11.53%, median ROCE of 13.32%. They set out the fundamental picture and are not a rating on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 13.54x |
| Benchmark Median P/E | 31.8x |
| Benchmark Average P/E | 46.93x |
| Benchmark P/E Range | 3.11x to 663.29x |
| Company P/B Ratio | 1.66x |
| Benchmark Median P/B | 2.91x |
| Company ROE | 16.3% |
| Benchmark Median ROE | 11.53% |
| Company ROCE | 17.16% |
| Benchmark Median ROCE | 13.32% |
| Company Market Capitalisation | Rs 15,697.36 crore |
| Benchmark Median Market Cap | Rs 819.72 crore |
Natco Pharma Ltd. (NATCOPHARM) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Natco Pharma Ltd. (NATCOPHARM) has a P/E ratio of 13.54x, which is below the benchmark median of 31.8x, a difference of -57.42%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Natco Pharma Ltd. (NATCOPHARM) has a ROE of 16.3%, which is above the benchmark median of 11.53%, a difference of +41.37%. Natco Pharma Ltd. (NATCOPHARM) has a ROCE of 17.16%, which is above the benchmark median of 13.32%, a difference of +28.83%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Alembic Pharmaceuticals Ltd. | APLLTD | 15,482.29 | 22.59 | 2.68 | 12.35 | 11.74 |
| Eris Lifesciences Ltd. | ERIS | 16,072.17 | 24.78 | 3.96 | 19.23 | 14.47 |
| Jubilant Pharmova Ltd. | JUBLPHARMA | 15,115.78 | 42.66 | 2.11 | 5.97 | 8.69 |
| Glenmark Life Sciences Ltd. | ALIVUS | 16,518.28 | 27.39 | 4.74 | 18.41 | 24.61 |
| Astrazeneca Pharma India Ltd. | ASTRAZEN | 14,717.5 | 86.77 | 16.28 | 23.02 | 31.24 |
Natco Pharma Ltd. (NATCOPHARM) has a P/E ratio of 13.54x compared with the displayed peer median of 27.39x. The comparison is relative and should not be read as a recommendation. Its ROE of 16.3% compares with a peer median of 18.41% across the companies shown in the table. ROCE stood at 17.16% versus the displayed peer median of 14.47%, providing a capital-efficiency comparison. Natco Pharma Ltd. (NATCOPHARM) has a market capitalisation of Rs 15,697.36 crore. Among the 5 peers shown, 2 have a larger market capitalisation.
Why Investors Are Watching Natco Pharma Ltd.
This section is about the repeated decline, not a trading call. Natco Pharma Ltd. 52 Week Low Streak has now stretched to a second straight session, the streak move is down 1.27% across the run, and the latest low at Rs 786.2 matches the day’s trough. Those facts keep the stock on the watchlist for anyone following yearly lows.
- Natco Pharma Ltd. 52 Week Low Streak has now stretched to a second straight session.
- The cumulative move across the run is down 1.27%.
- The latest low at Rs 786.2 matches the day’s trough.
- Valuation remains below the industry median on both P/E and P/B.
- ROE and ROCE remain above the benchmark medians.
About Natco Pharma Ltd.
Natco Pharma Ltd. operates in the Pharmaceuticals & Drugs industry within Healthcare. For readers tracking Natco Pharma Ltd. 52 Week Low Streak, that context matters because it helps frame the business against sector benchmarks rather than as a standalone price chart. The company’s market capitalisation of Rs 15,697.36 crore, P/E of 13.54 and P/B of 1.66 give the streak its valuation setting.
The company’s EPS of Rs 58.33 and book value of Rs 476.47 show the base that remains in place even as the share price keeps making fresh yearly lows. Natco Pharma Ltd. 52 Week Low Streak does not change those business inputs; it only changes how the market is pricing them at this point. That is why Natco Pharma Ltd. share price today should be read together with company financials, sector analysis and peer comparison.
Track Natco Pharma Ltd. Share Price on Univest
Use Natco Pharma Ltd. (NATCOPHARM) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.
| Metric | Value |
|---|---|
| Current Price | Rs 790 |
| Previous Close | Rs 789.6 |
| Today's Move | +Rs 0.4 (+0.05%) |
| Open | Rs 788.6 |
| High | Rs 794.85 |
| Low | Rs 786.2 |
| Market Capitalisation | Rs 15,697.36 crore |
Natco Pharma Ltd. (NATCOPHARM) traded at Rs 790 versus the previous close of Rs 789.6, a rise of 0.05%. The stock opened at Rs 788.6, reached a high of Rs 794.85, touched a low of Rs 786.2.
Use Natco Pharma Ltd. (NATCOPHARM) live share-price page, Univest 52-week-low screener and Univest market blogs to review live stock data, yearly-low lists and related market analysis.
Natco Pharma Ltd. 52 Week Low Streak can be followed alongside the latest share price, market capitalisation, valuation ratios and peer context on Univest. If the stock keeps printing new yearly lows, the next step is to watch whether the streak extends or whether price stabilises above the most recent trough.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
What does Natco Pharma Ltd. 52 Week Low Streak mean?
Ans. Natco Pharma Ltd. 52 Week Low Streak means the stock has set a fresh 52-week low in consecutive sessions. In this case, the pattern now spans two straight trading days and shows a repeated yearly low.
How many sessions has Natco Pharma Ltd. 52 Week Low Streak lasted?
Ans. Natco Pharma Ltd. 52 Week Low Streak has lasted for two consecutive sessions. The first low in the run was on 13 October 2026, and the latest session again marked a fresh 52-week trough.
By how much has Natco Pharma Ltd. 52 Week Low Streak moved?
Ans. The Natco Pharma Ltd. 52 Week Low Streak is down 1.27% across the streak. That figure captures the cumulative move over the consecutive lows and is more useful than only the latest intraday change.
What is the latest low in Natco Pharma Ltd. 52 Week Low Streak?
Ans. The latest low in Natco Pharma Ltd. 52 Week Low Streak is Rs 786.2. The same level was also the day’s low, so the stock again matched its fresh 52-week trough during the session.
Is there a confirmed company-specific reason for Natco Pharma Ltd. 52 Week Low Streak?
Ans. No company-specific cause is confirmed in the data for Natco Pharma Ltd. 52 Week Low Streak. The repeated low is confirmed, but the reason behind the continued decline is not established here.
How does Natco Pharma Ltd. 52 Week Low Streak look on valuation?
Ans. Natco Pharma Ltd. 52 Week Low Streak leaves the stock on 13.54 times earnings and 1.66 times book value. Both are below the latest Univest industry medians, which means the streak is happening at a lower valuation than many peers.
How do the return ratios compare in Natco Pharma Ltd. 52 Week Low Streak?
Ans. Natco Pharma Ltd. 52 Week Low Streak comes with ROE of 16.3% and ROCE of 17.16%. Both are above the benchmark medians in the same industry set. ROE stands at 16.3%.
How does Natco Pharma Ltd. 52 Week Low Streak compare with peers?
Ans. Natco Pharma Ltd. 52 Week Low Streak shows a lower P/E and P/B than several listed pharma peers in the benchmark set. That makes the stock look lower-valued on valuation, even as the repeated low keeps pressure on the price.
What should investors watch next in Natco Pharma Ltd. 52 Week Low Streak?
Ans. Investors should watch whether Natco Pharma Ltd. 52 Week Low Streak extends further or whether the stock starts trading above the latest trough. The key markers are the next session’s low and how the price behaves relative to the current.
